TICKERNERD
Menu
LPCNLPCNHealthcare · Biotechnology

LPCN Stock Forecast: Lipocine, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.11
+0.96% on the day

The 2 Wall Street analysts covering Lipocine, Inc. hold a median 12-month price target of $6 — +184.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$17.2M
Ticker Nerd rank
36 / 100
Median analyst target
$6.00
Analysts covering
2
Total return, dividends reinvested
1W
0.0%
1M
−3.7%
YTD
−73.7%
1Y
−29.9%
From 52W high
−81.3%
From 52W low
+8.8%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LPCN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lipocine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Revisions
88
Volatility
66
Accruals
48
Quality
47
Issuance
33
Momentum
16
Growth
10
Value
7

Size (90): Smaller than most of the companies we track.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LPCN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LPCN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26LPCNHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits +184.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Apr 2026HC Wainwright & Co.DowngradeNeutral—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025HC Wainwright & Co.ReiteratesBuy—
27 June 2025HC Wainwright & Co.ReiteratesBuy—
10 June 2025HC Wainwright & Co.ReiteratesBuy—
29 May 2025HC Wainwright & Co.AssumesBuy$8.00
24 Sept 2024Alliance Global PartnersInitiatesBuy$10
27 July 2023Cantor FitzgeraldReiteratesOverweight—
26 Aug 2021HC Wainwright & Co.MaintainsBuy$2.50 → $3.50
24 June 2021Cantor FitzgeraldInitiatesOverweight—
27 May 2021HC Wainwright & Co.MaintainsBuy$3.00 → $2.50
10 Dec 2020Ladenburg ThalmannUpgradeBuy—
27 May 2020HC Wainwright & Co.MaintainsBuy$2.00 → $3.00
29 Mar 2018Seaport GlobalInitiatesBuy—
27 Feb 2018Empire Asset ManagementUpgradeBuy—
11 Jan 2018Canaccord GenuityDowngradeHold—
7 Oct 2016H.C. WainwrightInitiatesBuy—
7 Oct 2016HC Wainwright & Co.InitiatesBuy—
12 Aug 2015Empire Asset ManagementMaintainsBuy$18 → $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LPCN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LPCN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Lipocine, Inc. (LPCN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
11.0×

Cheaper than 14% of US stocks

Price / book
0.8×

Cheaper than 79% of US stocks

EV / EBITDA
0.5×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−69.5%

Higher than 3% of US stocks

Earnings growth (YoY)
−69.5%

Higher than 6% of US stocks

Gross margin
−973.9%

Higher than 1% of US stocks

Operating margin
−1495.1%

Higher than 5% of US stocks

Net margin
−334.3%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−60.9%

Higher than 19% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LPCN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LPCNLipocine, Inc.$17.2M
36
TPSTTempest Therapeutics, Inc.$16.6M
36
PBMPsyence Biomedical Ltd.$16.5M
3
PTNPalatin Technologies, Inc.$16.5M
43
BIVIBioVie, Inc.$16.5M
22
CTXRCitius Pharmaceuticals, Inc.$16.5M
20
ADILAdial Pharmaceuticals, Inc.$16.3M
21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lipocine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LPCN news & analysis

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

PRNewsWire · 4 Aug 2026neutral

Lipocine announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update, including reporting topline results in April 2026 from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (brexanolone) for treating postpartum depression.

Why it matters — This update provides Lipocine watchers with the latest financial position and progress on LPCN 1154, the company's key Phase 3 candidate for postpartum depression.

Lipocine Appoints Michael J. Grissinger to Board of Directors

PRNewsWire · 3 Aug 2026positive

Lipocine Inc. announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.

Why it matters — The addition of a new board member could bring fresh expertise and governance perspective to the company as it advances its oral drug delivery platform.

FAQ

Frequently asked questions about LPCN stock

What is the LPCN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lipocine, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LPCN stock a buy right now?

Of the 2 analysts covering Lipocine, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lipocine, Inc. 36 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LPCN?

As at 22 Aug 2026, Lipocine, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will LPCN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +184.4% from the last close, and Ticker Nerd's factor model ranks Lipocine, Inc. 36 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LPCN stock forecast for 2030?

No analyst covering Lipocine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LPCN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has LPCN stock performed over the past year?

Lipocine, Inc. returned -29.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lipocine, Inc. do?

Lipocine Inc. is a pharmaceutical company specializing in the development and commercialization of innovative products through its proprietary oral drug delivery technology.

What is the latest news on LPCN?

The most recent item we track (PRNewsWire, 4 Aug 2026): "Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026". Lipocine announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update, including reporting topline results in April 2026 from its Phase 3 placebo-controlled trial (N=90) evaluating oral LPCN 1154 (brexanolone) for treating postpartum depression.

Company

About Lipocine, Inc.

Lipocine Inc. is a pharmaceutical company specializing in the development and commercialization of innovative products through its proprietary oral drug delivery technology. The primary function of Lipocine Inc. is to improve patient compliance by converting drugs traditionally administered via injection into oral dosage forms. This technology enhances the absorption and bioavailability of oral medications, thereby addressing common challenges faced in drug delivery. Lipocine Inc.'s portfolio includes products targeting testosterone deficiency and metabolic disorders, with some in advanced stages of clinical trials. Operating at the intersection of the pharmaceutical and biotechnology sectors, the company plays a vital role in advancing therapeutic solutions for endocrine and metabolic ailments. Lipocine's innovations hold significant market potential, as they aim to create more patient-friendly therapeutic options, which can lead to increased adoption and market acceptance. Headquartered in Salt Lake City, Utah, Lipocine Inc. continues to explore strategic partnerships to expand its reach and impact within the healthcare industry.

CEO Dr. Mahesh V. Patel Ph.D. · 14 employees · United States · https://www.lipocine.com